Sodium Chloride Solution 0.9%

This article explores the use of Sodium Chloride Solution 0.9% as a placebo comparator in clinical trials for the treatment of Acute Myeloblastic Leukemia (AML). The focus is on a study investigating the potential benefits of adding temsirolimus to standard chemotherapy for elderly patients with newly diagnosed AML. We’ll discuss the trial design, outcomes measured, and the role of the sodium chloride solution in this important research.

Table of Contents

What is Sodium Chloride Solution 0.9%?

Sodium Chloride Solution 0.9%, also known as normal saline or physiological saline, is a sterile solution of sodium chloride (salt) in water. The concentration of 0.9% means it contains 9 grams of sodium chloride per liter of water, which is similar to the salt concentration in the human body’s fluids[1].

Medical Uses

Sodium Chloride Solution 0.9% has various medical applications:

  • Intravenous Fluid Therapy: It’s commonly used to treat dehydration and maintain fluid balance in the body[2].
  • Medication Delivery: It serves as a diluent for many medications administered intravenously[2].
  • Nasal Irrigation: Used as a nasal spray to relieve congestion and moisturize nasal passages[1].
  • Wound Cleaning: It’s an effective solution for cleaning wounds and promoting healing[2].
  • Eye Rinse: Used to flush out irritants from the eyes[2].

Administration Methods

Sodium Chloride Solution 0.9% can be administered in several ways:

  • Intravenous (IV) Infusion: Directly into a vein, often used in hospital settings[2].
  • Subcutaneous (SC) Injection: Injected just under the skin[2].
  • Nasal Spray: Applied directly into the nostrils[1].
  • Topical Application: Used externally on wounds or skin[2].

Safety and Side Effects

Sodium Chloride Solution 0.9% is generally considered safe when used as directed. However, as with any medical treatment, there can be potential side effects or risks:

  • Fluid Overload: Excessive administration can lead to fluid accumulation in the body[3].
  • Electrolyte Imbalance: In rare cases, it may affect the balance of electrolytes in the body[3].
  • Injection Site Reactions: When administered via injection, there may be local reactions such as pain, redness, or swelling[3].

Always consult with a healthcare professional before using Sodium Chloride Solution 0.9%, especially if you have any pre-existing medical conditions or are taking other medications.

Use in Special Populations

Pregnancy and Breastfeeding: Sodium Chloride Solution 0.9% is generally considered safe during pregnancy and breastfeeding when used as directed. However, it’s always best to consult with a healthcare provider before use[4].

Pediatric Use: The solution is used in pediatric patients, including infants, but dosage and administration should be carefully monitored by healthcare professionals[5].

Ongoing Research

While Sodium Chloride Solution 0.9% is a well-established medical product, research continues to explore its potential uses and optimize its application:

  • COVID-19 Research: It’s being studied as a nasal spray in combination with other substances for potential use in treating COVID-19 and similar respiratory illnesses[1].
  • Vaccine Studies: The solution is often used as a placebo in vaccine trials, including recent studies on RSV vaccines[4].
  • Specialized Formulations: Researchers are exploring modified versions of the solution for specific medical applications[6].

As research progresses, our understanding of the best uses and applications of Sodium Chloride Solution 0.9% continues to evolve, potentially leading to improved patient care and treatment options.

Aspect Details
Study Type Double-blind, placebo-controlled, randomized, multicenter Phase II trial
Condition Acute Myeloblastic Leukemia (AML)
Target Population Elderly patients (over 60 years) with newly diagnosed AML
Intervention Temsirolimus added to standard chemotherapy
Comparator Sodium Chloride Solution 0.9% (placebo) added to standard chemotherapy
Primary Outcomes Median Event Free Survival (EFS) and event-free survival probability
Secondary Outcomes Response rates, survival rates, molecular remissions, adverse events
Follow-up Duration One year after start of study treatment

Ongoing Clinical Trials on Sodium Chloride Solution 0.9%

  • A Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness

    Recruiting

    1 1 1
    Germany Poland Spain
  • Study on the Effectiveness of Autovaccines Compared to Antibiotics for Patients with Hip or Knee Prosthesis Infections

    Recruiting

    3 1 1 1
    Spain
  • Study of Botulinum Toxin and Saline Solution for Erectile Dysfunction in Patients Unresponsive to Standard Treatments

    Recruiting

    2 1 1
    Spain
  • Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

    Recruiting

    2 1 1 1
    France The Netherlands Spain
  • Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock

    Not yet recruiting

    3 1 1
    Investigated diseases:
    France Germany Italy Spain
  • Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

    Not yet recruiting

    2 1 1
    France
  • Study of botulinum toxin type A injections to prevent scarring in patients after heart surgery with sternotomy

    Not yet recruiting

    3 1 1
    France
  • Study of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not yet recruiting

    2 1 1 1
    Hungary Italy Poland
  • Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Finland Germany The Netherlands Poland Sweden
  • Study on the Safety and Immune Response of mRNA-1345 and mRNA-1365 for Infants with Acute Lower Respiratory Infection Aged 5 to 24 Months

    Not recruiting

    1 1 1
    Latvia Poland Spain

Glossary

  • Acute Myeloblastic Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells that interfere with the production of normal blood cells.
  • Temsirolimus: An experimental drug being tested in this trial, also known by the brand name Torisel, which is added to standard chemotherapy to potentially improve treatment outcomes for AML patients.
  • Placebo Comparator: A substance or treatment that looks identical to the experimental treatment but contains no active ingredients. In this case, Sodium Chloride Solution 0.9% is used as the placebo comparator.
  • Event Free Survival (EFS): The length of time after treatment during which no specified events (such as disease progression or death) occur in a patient.
  • Complete Remission (CR): A state where there is no evidence of disease and blood counts have returned to normal levels after treatment.
  • Relapse Free Survival (RFS): The length of time after achieving complete remission during which no relapse (return of the disease) occurs.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Molecular Remission: A state where no evidence of the disease can be detected at the molecular level, often using highly sensitive tests.
  • Adverse Events: Any unfavorable or unintended sign, symptom, or disease that occurs during the study, whether or not it is related to the treatment being studied.

References

  1. http://clinicaltrials.eu/trial/study-on-nitric-oxide-and-saline-nasal-sprays-for-treating-covid-19-and-similar-illnesses-in-primary-care-patients/
  2. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-mrna-3705-for-patients-with-methylmalonic-acidemia-mma/
  3. http://clinicaltrials.eu/trial/study-of-ly3454738-for-treating-moderate-to-severe-atopic-dermatitis-in-adults/
  4. http://clinicaltrials.eu/trial-id/2023-505359-37-00
  5. http://clinicaltrials.eu/trial-id/2022-502022-41-00
  6. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-73763989-and-tenofovir-alafenamide-in-patients-with-hepatitis-b-and-d-co-infection/